NCT02566304 - Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 13, 2015

Primary Completion Date

February 13, 2024

Study Completion Date

February 13, 2024

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia in RemissionAplastic AnemiaChronic Myelomonocytic LeukemiaHodgkin LymphomaIndolent Non-Hodgkin LymphomaMalignant NeoplasmMyelodysplastic SyndromeMyeloproliferative NeoplasmPlasma Cell MyelomaRefractory AnemiaRefractory Anemia With Excess BlastsRefractory Anemia With Ring SideroblastsRefractory Cytopenia With Multilineage DysplasiaRefractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts

Interventions

DRUG

Fludarabine

Given IV

RADIATION

Total-Body Irradiation

Undergo TBI

BIOLOGICAL

T Cell-Depleted Donor Lymphocyte Infusion

Undergo DLI

DRUG

Cyclophosphamide

Given IV

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo PBSC transplant

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo PBSC transplant

DRUG

Tacrolimus

Given PO

DRUG

Mycophenolate mofetil

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

19107

Thomas Jefferson University, Philadelphia

All Listed Sponsors

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER